Bioequivalence Research Center to open in St. Petersburg
The RVC Biofund announces
about the first deal in St. Petersburg
LLC "Biopharmaceutical investments RVC" ("Biofund RVC") Together with a group of private investors, he is creating a Bioequivalence Research Center (BioEc) in St. Petersburg, which will allow conducting Phase I clinical trials in accordance with international GCP standards.
In June 2010, the Board of Directors of JSC RVC approved the concept of the RVC Biofund. At the beginning of 2011, the foundation began its activities. The investment focus of RVC Biofund covers innovative biopharmaceutical companies and service companies providing contract laboratory, analytical and consulting services to biotechnological, pharmaceutical and medical companies.
"The attractiveness of the Russian market for clinical trials of bioequivalence and early phases in comparison with later phases remains low – there are simply very few centers ready to provide a service that meets the international quality standard in a short time," says Egor Beketov, Director of the RVC Biofund.
Existing clinical research centers – as a rule, state research institutes specialized in the later stages of clinical research – cannot meet the increasing market demand. The features of the company being created consist in strict adherence to international standards, as well as in greater speed of research and flexibility in relationships with customers. The project team includes a number of specialists with extensive experience in the industry, and a number of agreements have been concluded with the world's leading CRO and pharmaceutical companies to conduct consultations and staff training.
"Our center will be able to take its rightful place in the clinical research market, first of all, thanks to a professional team," commented Ivan Sardaryan, Director of BioEc. – We will promptly respond to market demands and try to meet the highest requirements of customers. To date, we are already preparing several contracts, both with domestic and foreign manufacturers."
The new Bioequivalence Research Center fits seamlessly into the development concept of St. Petersburg as one of the leaders of biotechnological innovations in Russia. The rapidly developing pharmaceutical cluster of St. Petersburg will certainly contribute to the creation of additional demand for the Center's services.
Thus, this project not only creates a potentially profitable market company, but also contributes to the development of public-private partnerships, and also makes a significant contribution to the innovative infrastructure of the region, which meets the main strategic goals of RVC and its subsidiary, the RVC Biofund.
"The pharmaceutical market today is one of the most promising, it has attracted the attention of international and Russian investors. But in Russia, the service infrastructure is still poorly developed, which hinders the development of the biotechnology sector as a whole. The elimination of barriers, the creation of service companies providing world–class commercial services to biopharmaceutical innovative companies is the strategic goal of the RVC Biofund. We are counting on a positive synergetic effect from the interaction of the state development Institute and private business," said Yan Ryazantsev, Director of the Investment Department of JSC RVC.
Portal "Eternal youth" http://vechnayamolodost.ru11.09.2012